OVIT (OncoVista Innovative Therapies) Net Income From Continuing Operations: $-3.27 Mil (TTM As of Sep. 2015)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is OncoVista Innovative Therapies Net Income From Continuing Operations?

OncoVista Innovative Therapies OVIT Net Income From Continuing Operations is $-3.27 Mil as of Sep. 2015.

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. OncoVista Innovative Therapies's net income from continuing operations for the three months ended in Sep. 2015 was $-0.33 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Sep. 2015 was $-3.27 Mil.

OncoVista Innovative Therapies Net Income From Continuing Operations Historical Data

* Premium members only.

The historical data trend for OncoVista Innovative Therapies's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoVista Innovative Therapies Net Income From Continuing Operations Chart

OncoVista Innovative Therapies Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.38 -2.03 -1.63 -1.45 -2.54

OncoVista Innovative Therapies Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 -1.57 -0.28 -1.10 -0.33

OncoVista Innovative Therapies Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income From Continuing Operations of $-3.27 Mil mean?
OncoVista Innovative Therapies (OVIT) has a Net Income From Continuing Operations of $-3.27 Mil as of Sep. 2015. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for OncoVista Innovative Therapies and its competitors.
Is OncoVista Innovative Therapies' Net Income From Continuing Operations too high?
OncoVista Innovative Therapies' current Net Income From Continuing Operations is $-3.27 Mil.
How does OncoVista Innovative Therapies' Net Income From Continuing Operations compare to RSPI and HSTC?
OncoVista Innovative Therapies' Net Income From Continuing Operations of $-3.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Biotechnology company?
A good Net Income From Continuing Operations depends on the Biotechnology industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for OncoVista Innovative Therapies and its competitors. OncoVista Innovative Therapies's current Net Income From Continuing Operations is $-3.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoVista Innovative Therapies stock overvalued right now?
OncoVista Innovative Therapies (OVIT) has a current Net Income From Continuing Operations of $-3.27 Mil. The current Net Income From Continuing Operations is $-3.27 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For OncoVista Innovative Therapies (OVIT), the current Net Income From Continuing Operations is $-3.27 Mil as of Sep. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoVista Innovative Therapies Business Description

Address 14785 Omicron Drive, Suite 104, San Antonio, TX, USA, 78245
OncoVista Innovative Therapies Inc is a biopharmaceutical company. It is engaged in developing anticancer therapies by utilizing tumor-associated biomarkers.